BONE.MARROW.MICROENVIRONMENT.LYMPHOCYTES.MEASURED.BY.FLOW.
CYTOMETRY.CAN.PREDICT.EARLY.RELAPSE.IN.DIFFUSE.LARGE.B.CELL.
LYMPHOMA.PATIENTS.
.
Laura%Korin1,%Santiago%Cranco2,%Maria%Lucia%Fuente2,%Evelina%Babuin2,%Adriana%Vitriu2,%Paola%Ochoa2,%
Andrea% Novoa2,% Paula% Tempra2,% Maria% Belen% Venegas2,% Anahi% Vijnovich% Baron3,% Fernando% Diaz%
Couselo2,%Norma%Tartas2,%Rosario%Custidiano1,%Cecilia%Foncuberta1%and%Julio%Cesar%Sanchez%Avalos1%
%
(1)Instituto1Alexander1Fleming,1Buenos1Aires,1Argentina,1(2)Instituto1Alexander1Fleming,1Buenos1aires,1
Argentina,1(3)Cepacit,1Buenos1aires,1Argentina1
%
PURPOSE:%Early%rituximab%failure%in%DLBCL%showed%disappointing%outcomes.%Data%regarding%
the% role% of% variables% related% to% the% host% immune% response% in% identifying% this% high% risk%
subgroup% is% limited.% We% sought% to% determine% the% prognostic% impact% on% the% risk% of% early%
relapse%of%the%percentage%(%)%of%immune%cells%in%preUtreatment%bone%marrow%(BM)%aspirates%
of%DLBCL%patients%measured%by%flow%cytometry%(FC).%
METHODS:% Retrospective% analysis% of% patients% with% DLBCL% and% available% BM% aspiration% FC%
data%at%diagnosis%who%received%immunochemotherapy%at%our%institution%between%2012%and%
2019.% FC% analysis% was% performed% with% 8Ucolor% panels% following% international% Euroflow%
protocols.%%%of%BM%immune%cells%was%compared%to%normal%values%(Matarraz%et%al,%Cytometry%
part%B,%2010)%and%analyzed%as%low,%normal%and%high.%Odds%ratio%for%ER%(within%a%year)%was%
calculated% using% logistic% regression.% Survival% analysis% was% estimated% with% KaplanUMeier%
method.%
RESULTS:%Pts%characteristics%(n:%106)%are%summarized%in%Table%1.%Seventeen%patients%had%BM%
involvement%at%diagnosis.%Median%PFS%and%OS%were%not%reached,%75th%percentile%of%12.7%and%
27.8%months,%respectively.%ER%was%documented%in%25%pts.%Median%follow%up%time%was%34.4%
months%(range:%2.7U60).%No%statistical%difference%was%observed%in%the%percentage%of%immune%
cells%in%involved%vs%not%involved%BM.%
The%odds%of%ER%was%4%times%higher%in%pts%with%low%BM%T%lymphocytes%(95%%CI%1.47U10.84,%p:%
0.006)%and%2.8%times%higher%in%pts%with%low%polyclonal%B%lymphocytes%(95%%CI%1.07U7.58,%p:%
0.036).%On%the%contrary,%goodUvery%good%RUIPI%showed%a%protective%effect%with%an%odds%ratio%
for% ER% of% 0.22% (95%% CI% 0.08U0.61,% p:% 0.003).% No% correlation% was% found% between% the% %% of%
monocytes% or% neutrophils% and% the% risk% of% experiencing% early% treatment% failure.% On%
multivariate%analysis%both%low%BM%T%lymphocyte%%%OR%5.18%(95%%CI%1.45U18.53,%p:%0.011)%
and%the%RUIPI%subgroup%OR%0.21%in%goodUvery%good%RUIPI%(95%%CI%0.06U0.71,%p:%0.012)%were%
predictive%of%ER.%
CONCLUSIONS:% Low% BM% T% lymphocyte% %% and% poor% RUIPI% identified% a% subgroup% of% pts% with%
extremely% poor% results.% These% two% variables% presented% at% diagnosis% might% be% used% as%
prognostic% factors% of% ER% in% DLBCL.% In% the% future,% therapies% that% could% target% the% crosstalk%
between% lymphoma% cells% and% the% BM% microenvironment% might% represent% an% encouraging%
strategy%to%improve%outcomes.%%
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES